PTC Therapeutics | PTCT - Current Liabilities


PTC Therapeutics reported $866.24M in Current Liabilities for its fiscal quarter ending in September of 2025.





Current Liabilities Change Date
Acadia Pharmaceuticals USD 356.58M 26.56M Sep/2025
Alnylam Pharmaceuticals USD 1.56B 254.63M Sep/2025
Amgen USD 21.79B 1.32B Sep/2025
Biogen USD 3.29B 106.3M Sep/2025
BioMarin Pharmaceutical USD 798.44M 114.19M Sep/2025
Cytokinetics USD 142.14M 11.08M Sep/2025
Daiichi Sankyo JPY 778.55B 77.51B Dec/2025
Gilead Sciences USD 12.3B 1.11B Sep/2025
Incyte USD 1.34B 60.11M Sep/2025
Ionis Pharmaceuticals USD 903.46M 6.22M Sep/2025
Ironwood Pharmaceuticals USD 242.5M 9.98M Sep/2025
Novartis USD 32B 286M Sep/2025
Pfizer USD 36.6B 1.13B Sep/2025
PTC Therapeutics USD 866.24M 238.44M Sep/2025
Roche Holding CHF 28B 421M Dec/2025
Sarepta Therapeutics USD 921.42M 1.48M Sep/2025
TG Therapeutics USD 156.81M 15.08M Sep/2025
Ultragenyx Pharmaceutical USD 340.02M 46.78M Sep/2025
Vertex Pharmaceuticals USD 4.48B 336.9M Sep/2025
Xencor USD 86.48M 9.6M Sep/2025